Background: This National Cancer Database (NCDB) analysis evaluates the clinical
| INTRODUCTION
Pancreatic adenocarcinoma, the fourth leading cause of cancer death in the United States, is a treatment challenge with a dismal median survival of 12.4 months. 1 Surgical resection is considered the only potentially curative approach, though survival rates are modest, with a 5-year overall survival (OS) of 7%-17%. [2] [3] [4] With local failure rates as high as 73% after surgery, [2] [3] [4] various adjuvant therapies, including chemoradiation (CRT), have been investigated in clinical trials and institutional studies as a means to address the poor clinical outcomes in patients with pancreatic adenocarcinoma. Several reports have demonstrated improved OS with the use of adjuvant chemoradiation, with median OS times ranging from 19.5 to 25.2 months. [5] [6] [7] [8] [9] Several National Cancer Database (NCDB) studies have similarly shown improved OS with adjuvant CRT. [10] [11] [12] Literature for the role of chemotherapy (C) before CRT for resected pancreatic adenocarcinoma is limited. A phase III study of adjuvant fluorouracil vs gemcitabine, given for 3 weeks followed by CRT, and then an additional 3 months of C, found no difference in OS with either agent. 13 A NCDB analysis, did however, report a survival benefit with chemotherapy prior to CRT for locally advanced pancreatic cancer. 14 Due to a lack of comparative studies, the value of C prior to CRT specifically for early-stage pancreatic cancer remains unclear. This study compares the outcomes of patients who received C + CRT vs those who received C or CRT alone for stage I-II, resected pancreatic cancer.
| METHODS

| Patient population
The NCDB registry was used to identify patients with pancreatic adenocarcinoma diagnosed between 2004 and 2015 (the most recent dataset available at the time of this study). The NCDB is a nationwide cancer database that captures approximately 70% of newly diagnosed cancer cases in the United States and includes 34 million historical records. 15 It provides access to de-identified datasets from Commission on Cancer-accredited programs through online application. This study was exempt from institutional review board review. Our patient selection criteria are shown in Figure 1 . We selected from our initial query of patients with stage I-II, clinical T1-3N0-1M0 pancreatic adenocarcinoma who had been treated with curative-intent resection followed by adjuvant chemotherapy and conventionally fractionated radiation therapy. American Joint Committee on Cancer (AJCC) 6th and 7th editions were used to determine stage I-II disease in 2004-2015.
Whipple surgery was defined as local or partial pancreatectomy and duodenectomy with partial gastrectomy.
Whipple-variant surgery was characterized as partial pancreatectomy with duodenectomy, total pancreatectomy alone, or total pancreatectomy with subtotal gastrectomy or duodenectomy. 16 Patients treated with chemotherapy or radiation therapy within 30 days of each other were considered to have received adjuvant CRT alone. Those who were treated with adjuvant chemotherapy within 31-180 days prior to the radiation therapy were defined as having received C + CRT. 14 Patients who received adjuvant chemotherapy more than 180 days prior to adjuvant radiation therapy were excluded. Patients were excluded if they had incomplete follow-up data, missing radiation dose or fractionation information, incomplete data on the number of days between diagnosis and treatments, or missing information regarding surgical margins. Patients treated with palliative-intent or with neoadjuvant chemotherapy or radiation were also excluded. To address immortal time bias, those with postdiagnosis survival duration of <3 months were not included. 17 Baseline patient, tumor, and treatment characteristics for analysis included the following: facility type, age, gender, race, insurance type, income level, residential setting, Charlson-Deyo comorbidity score (CDS), year of diagnosis, primary tumor location within pancreas, tumor grade, tumor size, clinical T and N stages, pathologic T and N stages, number of biopsy-positive lymph nodes, surgery type, surgical margin, total radiation dose, and chemotherapy use. Surgical margin was categorized as either negative (R0) or positive (R1, R2, positive margin not otherwise specified). Patients were stratified by age ≥66 or <66 years, and tumor size <3.1 or ≥3.1 cm based on their median values. The household income level of each patient's residential area was based on the 2012 American Community Survey data adjusted for inflation (the most recent data at the time of this study) and was stratified above or below the median value of $48 000. CA 19-9 factor was coded by the NCDB with a cut off of <98 or ≥98 Units/mL, although CA 19-9 was not used for propensity score matching due to missing data in 3064 (54.1%) of patients. Local and distant failure/progression information is also unable to be analyzed based on data from the NCDB. Important prognostic variables such as the patient's initial performance status, type and duration of chemotherapy received, and toxicity outcomes are unavailable in the NCDB. The primary endpoint was overall survival (OS), time between the diagnosis and the last follow-up or death.
| Statistical analysis
OS was evaluated using the Kaplan-Meier method and logrank tests. Fisher's exact test and Mann-Whitney U test were used to compare categorical and continuous variables between two treatment cohorts, respectively. Logistic regression univariable (UVA) and multivariable analyses (MVA) were used to determine potential factors that predicted the use of postoperative chemotherapy and were reported as odds ratio (OR). Cox proportional hazard UVA and MVA were used to determine factors that predict the OS and were reported as hazards ratio (HR). MVA was initially constructed using all statistically significant variables from UVA and was finalized using a backward stepwise elimination. Only patients with complete information on such variables were included. Potential interactions between the treatment and other covariates were examined using Cox MVA by adding interaction terms. 18 When the interaction terms were statistically significant, the final Cox MVA model was re-analyzed for each subgroup of covariates, and a forest plot was constructed to illustrate the direction and magnitude of treatment effects. 18 To minimize selection bias, propensity score matching was used. Match-pairs were constructed by matching baseline patient, tumor, and treatment characteristics. Variables of interest include facility type, year of diagnosis, age, CDS, tumor grade, tumor size, surgery type, chemotherapy use, total radiation dose, pathologic T and N stages, and additional variables that were statistically significant in Cox proportional hazard MVA results for each cohort. All matching was performed in a 1:1 ratio without any replacement and was based on nearest neighbor method with a caliper distance of 0.2 of the standard deviation of the logit of the propensity score. 19 Matching was performed using MatchIt package (version 3.0.1). R software (version 3.5.0, R Foundation for Statistical Computing, Vienna, Austria) was used for all aforementioned analyses. All P values were two-sided. A P value <0.05 was considered statistically significant.
| RESULTS
A total of 5667 patients with resected clinical stage I-II, T1-3N0-1M0 pancreatic adenocarcinoma were identified for analysis. Of those, adjuvant C, CRT, and C + CRT were delivered to 3031, 1307, and 1329 patients, respectively. 
patients received RT to the pancreas, and 420 (221 for CRT, 199 for C + CRT) patients received RT to the abdomen (not otherwise specified); therefore, 93.7% (2470/2636) of patients received RT to the pancreas or abdomen. A total of 107 (107/1307 = 8.2%) and 106 (106/1329 = 8.0%) patients received <45 Gy in cohort CRT and C + CRT, respectively. On logistic MVA for all patients, patients with diagnosis between 2008 and 2011 (OR 2.17, P < 0.001) and 2012 and 2015 (OR 1.99, P < 0.001), pathologic nodal diseases (OR 1.37, P < 0.001 for 1-3 positive nodes; OR 1.32, P = 0.0034 for 4+ positive nodes), positive surgical margin (OR 1.25, P = 0.0062), and receipt of multiagent chemotherapy (OR 2.01, P < 0.001) were more likely to receive C + CRT compared to C or CRT alone. Patients treated at academic facilities (OR 0.73, P < 0.001), older than 66 years old (OR 0.66, P < 0.001), from low-income regions (OR 0.83, P = 0.0083), with pancreatic tail disease (OR 0.68, P = 0.0011), and poorly differentiated histology (OR 0.74, P = 0.019) were less likely to undergo C + CRT. On Cox MVA for all patients (Table 3) , those older than 66 years old (HR 1.14, P < 0.001), from low-income regions (HR 1.10, P = 0.0082), with higher CDS (HR 1.23, P = 0.0017), moderately (HR 1.18, P = 0.018) or poorly differentiated (HR 1.51, P < 0.001) disease, tumors larger than 3.1 cm (HR 1.26, P < 0.001), pathologic positive nodal diseases (HR 1.46, P < 0.001 for 1-3 positive nodes; HR 1.79, P < 0.001 for 4+ positive nodes), high CA 19-9 (≥98 U/ mL) (HR 1.30, P < 0.001), and positive surgical margins (HR 1.47, P < 0.001) were associated with worse mortality. When compared to C + CRT, those treated with C (HR 1.31, P < 0.001) or CRT alone (HR 1.24, P < 0.001) had worse survival outcomes. Improved overall survival was observed in those treated at academic facilities (HR 0.83, P < 0.001) and pathologic T1-2 diseases (HR 0.87, P = 0.0051).
After Cox MVA, treatment interactions were observed in positive nodal disease subgroups 
| Cohort C
The C group had a median follow-up of 34.7 months (IQR 22.9-54.6), and the C + CRT group had that of 39.7 months for the C + CRT group (log-rank P < 0.001). OS at 2 years was 48.8% for the C group and 53.1% for the C + CRT group. A total of 2152 patients were matched. All variables were well balanced between these two groups ( Table 1) . The overall median follow-up for the matched patients was 36.7 months (IQR 24.7-54.5). The median OS was 20.0 months (IQR 11.5-33.6) for the C group and 23.3 months (IQR 15.6-39.2) for the C + CRT group (Figure 3 ; log-rank P < 0.001). OS at 2 years was 45.2% for the C group and 52.3% for the C + CRT group.
T A B L E 1 (Continued) T A B L E 2 Baseline characteristics for cohort CRT
| Cohort CRT
The CRT and C + CRT groups had a median follow-up of 45.2 and 39.7 months, respectively. The median OS was 21.1 months (IQR 12.5-36.0) for the CRT group and 23.4 months (15.6-39.3) for the C + CRT group (log-rank P < 0.001). OS at 2 years was 46.2% and 53.1% for the CRT and C + CRT groups, respectively.
A total of 1774 patients were matched. All variables were well balanced ( Table 2 
| DISCUSSION
To our knowledge, this is the first study to compare adjuvant C + CRT vs C or CRT alone for stage I-II resected pancreatic cancer. This study suggests a survival benefit favoring the use of C + CRT for resected pancreatic cancer, specifically in cases of pathologically node-positive disease.
The C + CRT cohort included over 70% patients with pathologically staged T3 and N1 disease, which are notably associated with worse prognosis. [20] [21] [22] Despite this, the C + CRT still had better OS compared to the CRT alone cohort. The median OS was 23 months, which is comparable to or better than previously reported survival outcomes for adjuvant CRT alone.
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The use of adjuvant C in addition to CRT has only been investigated in a few studies. to receive C + CRT compared to those diagnosed between 2004 and 2007. A prior institutional study showed that delaying CRT until after >1 cycle of adjuvant C is not associated with worse mortality when compared to adjuvant CRT only. 24 Our study is the first report showing that delaying CRT until after 30-180 days of adjuvant C may have survival benefits.
Our Cox MVA results (Table 3) showed that moderately or poorly differentiated tumors, larger tumor size, and pathologic N1 disease were adverse prognostic factors for mortality. This association is consistent with prior studies. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Older age, more medical comorbidities, low income, and positive surgical margins were also shown to be associated with worse mortality in our study, and this finding is also 
T A B L E 3 (Continued)
F I G U R E 2 Forest plot for subgroup analysis. C, adjuvant chemotherapy; C + CRT, adjuvant chemotherapy followed by chemoradiation; CI, confidence interval; CRT, chemoradiation; HR, hazards ratio; LN, lymph node; No., number of patients consistent with other reports. [36] [37] [38] [39] In this study, treatment at academic facilities was an independent favorable prognostic factor for OS. This finding is consistent with prior analyses showing improved outcomes at high volume centers related to better surgical outcomes, which may explain why living in a rural area was associated with worse mortality. [40] [41] [42] Although additional factors contributing to improved OS at academic facility may include patient self-selection, higher socioeconomic status and/or performance status. From our logistic MVA results, patients with pathologic T3-4N1 diseases and positive surgical margins were more likely to receive C + CRT. A prior study has also shown that patients with a higher disease burden were more likely to receive adjuvant therapies. 43 In our study, the use of multiagent chemotherapy was not a favorable prognostic factor for survival. This finding is in contrast to theEuropean Study Group for Pancreatic Cancer-4 (ESPAC-4) trial. Despite including 61% of patients with positive surgical margins and 79% with N1 disease in the ESPAC-4 trial, adjuvant gemcitabine combined with capecitabine significantly improved survival. 28 In NCDB, multiagent chemotherapy was recorded as the first course, and it is possible that some chemotherapy regimens were changed during the course of treatments. This change in chemotherapy regimens is not recorded in NCDB, which may explain this discrepancy.
| Limitations
This study has a number of limitations, many of which are inherent to performing a retrospective review. Various potential prognostic factors, such as smoking and alcohol history, performance status, molecular tests, and the type and duration of chemotherapy, are not recorded by the NCDB. Outcomes such as local or distant recurrences, toxicity, and cancer-specific survival were also unavailable. More than half of the CA 19-9 values, an important prognostic factor for resectability and survival, were missing from this dataset and could not be included for propensity score matched analysis. 27, [44] [45] [46] [47] The NCDB also does not include information on disease progression; therefore, this study cannot address the possibility of a patient received RT for progression of disease on chemotherapy. This limitation is inherent to all NCDB analyses and limit interpretation of our findings. Further, RT may have been palliative-intent for a minority of the included patients based on site and dose of RT, but since both CRT and C-CRT had similar numbers of patients receiving <45 Gy, it is unlikely these patients would change the conclusions of this study. Since the NCDB is not a population-based database, our findings may not be generalized to other patient populations. Up to 79% of patients in RTOG 9704 experienced chemotherapy-related toxicity. A meta-analysis of adjuvant treatments for resected pancreatic adenocarcinoma also showed significant toxicity with the addition of chemotherapy to chemoradiation. 48 It is possible that those patients who received C + CRT may have had a better initial performance status in order to tolerate the additional toxicity of chemotherapy, thus leading to better survival outcomes compared to those receiving C or CRT alone. 13 This potential confounder may also explain the improved survival seen in other institutional studies. 6, 23 However, it is unlikely that improved performance status was F I G U R E 3 Overall survival for cohort C after matching.
P < 0.001. C, adjuvant chemotherapy; C + CRT, adjuvant chemotherapy followed by chemoradiation
F I G U R E 4
Overall survival for cohort CRT after matching.
P < 0.001. CRT, adjuvant chemoradiation; C + CRT, adjuvant chemotherapy followed by chemoradiation the only factor contributing to this overall survival benefit, since patients with node negative diseases would have also favored C + CRT in our study. In addition, no treatment interaction was seen with CDS or with age on Cox MVA in this study, nor were CDS or age predictors on logistic MVA for the receipt of C + CRT. Since all patients in our study underwent adjuvant therapies, the difference in performance status between the C + CRT and other regimens is unlikely to independently explain the survival benefits.
| CONCLUSION
In summary, this analysis suggests improved survival for adjuvant C + CRT following resected pancreatic cancer with node-positive disease. More studies may be warranted to investigate the benefit of adding adjuvant chemotherapy to CRT and the ideal sequencing of these regimens.
